ATXS Astria Therapeutics Inc
Price (delayed)
$5.4
Market cap
$304.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.68
Enterprise value
$250.28M
Highlights
The company's EPS rose by 31% YoY and by 23% QoQ
Astria Therapeutics's debt has decreased by 5% QoQ
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
The net income has declined by 29% year-on-year but it has increased by 6% since the previous quarter
ATXS's quick ratio is down by 22% from the previous quarter and by 20% YoY
Key stats
What are the main financial stats of ATXS
Market
Valuations
Earnings
Shares outstanding
56.43M
Market cap
$304.74M
Enterprise value
$250.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.95
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$111.56M
Net income
-$94.26M
EBIT
-$94.26M
EBITDA
-$94.26M
Free cash flow
-$81.54M
Per share
Balance sheet
Liquidity
EPS
-$1.68
EPS diluted
-$1.68
Free cash flow per share
-$1.45
Book value per share
$5.66
Revenue per share
$0
TBVPS
$6.1
Total assets
$342.36M
Total liabilities
$23.1M
Debt
$5.35M
Equity
$319.26M
Working capital
$315.51M
Debt to equity
0.02
Current ratio
17.49
Quick ratio
17.15
Net debt/EBITDA
0.58
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26%
Return on equity
-27.4%
Return on invested capital
-37.5%
Return on capital employed
-29.2%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ATXS stock price
How has the Astria Therapeutics stock price performed over time
Intraday
1.12%
1 week
-13.6%
1 month
-16.15%
1 year
-60.03%
YTD
-39.6%
QTD
1.12%
Financial performance
How have Astria Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$111.56M
Net income
-$94.26M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 34% year-on-year but it rose by 4% since the previous quarter
The net income has declined by 29% year-on-year but it has increased by 6% since the previous quarter
Growth
What is Astria Therapeutics's growth rate over time
Valuation
What is Astria Therapeutics stock price valuation
P/E
N/A
P/B
0.95
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS rose by 31% YoY and by 23% QoQ
The P/B is 45% lower than the last 4 quarters average of 1.7 and 28% lower than the 5-year quarterly average of 1.3
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
Efficiency
How efficient is Astria Therapeutics business performance
The ROIC has soared by 73% YoY and by 25% QoQ
ATXS's ROA is up by 22% YoY and by 12% QoQ
Astria Therapeutics's return on equity has increased by 21% YoY and by 11% QoQ
Dividends
What is ATXS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ATXS.
Financial health
How did Astria Therapeutics financials performed over time
ATXS's total liabilities has soared by 100% year-on-year and by 16% since the previous quarter
ATXS's total assets is up by 34% YoY but it is down by 5% QoQ
Astria Therapeutics's debt is 98% lower than its equity
Astria Therapeutics's equity has increased by 31% YoY but it has decreased by 7% QoQ
Astria Therapeutics's debt has decreased by 5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.